Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Study evaluates efficacy of isotretinoin in improving COVID-19 outcomes

Study evaluates efficacy of isotretinoin in improving COVID-19 outcomes

14 Mar 2022
Study explores SARS-CoV-2 viremia kinetics

Study explores SARS-CoV-2 viremia kinetics

14 Mar 2022
Study explores neutralization of SARS-CoV-2 Omicron variant by subunit vaccine boosters

Study explores neutralization of SARS-CoV-2 Omicron variant by subunit vaccine boosters

14 Mar 2022
Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

14 Mar 2022
Current evidence that vitamin D is effective against COVID-19 neurological sequelae

Current evidence that vitamin D is effective against COVID-19 neurological sequelae

14 Mar 2022
Conformational variation of the SARS-CoV-2 energy landscape

Conformational variation of the SARS-CoV-2 energy landscape

14 Mar 2022
Efficient inactivation of SARS-CoV-2 on N95 masks by an antimicrobial coating

Efficient inactivation of SARS-CoV-2 on N95 masks by an antimicrobial coating

14 Mar 2022
COVID-19 incidence in K-12 schools in mask-required vs. mask-optional settings

COVID-19 incidence in K-12 schools in mask-required vs. mask-optional settings

14 Mar 2022
Factors influencing cross-protective serological immunity against SARS-CoV-2 variants in Asians

Factors influencing cross-protective serological immunity against SARS-CoV-2 variants in Asians

14 Mar 2022
Modeling study assesses the effectiveness facemasks before and after COVID-19 vaccination

Modeling study assesses the effectiveness facemasks before and after COVID-19 vaccination

14 Mar 2022
Role of carboxypeptidase U in severe COVID-19

Role of carboxypeptidase U in severe COVID-19

14 Mar 2022
In silico screening of natural ACE2 inhibitors

In silico screening of natural ACE2 inhibitors

14 Mar 2022
Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

14 Mar 2022
Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

14 Mar 2022
The impact of PLEX on the survival of patients with severe COVID-19 and the effect on the cytokine release syndrome

The impact of PLEX on the survival of patients with severe COVID-19 and the effect on the cytokine release syndrome

14 Mar 2022
Exploring SARS-CoV-2 spike evolution in relation to sensitivity to antiviral restriction factors

Exploring SARS-CoV-2 spike evolution in relation to sensitivity to antiviral restriction factors

11 Mar 2022
In silico screening and testing of FDA approved drugs inhibiting SARS-CoV-2 spike protein cleavage

In silico screening and testing of FDA approved drugs inhibiting SARS-CoV-2 spike protein cleavage

11 Mar 2022
Study indicates a 100 µg mRNA-1273 booster has acceptable safety and robust antibody response against SARS-CoV-2

Study indicates a 100 µg mRNA-1273 booster has acceptable safety and robust antibody response against SARS-CoV-2

11 Mar 2022
Novel genetic relationships with severe SARS-CoV-2

Novel genetic relationships with severe SARS-CoV-2

11 Mar 2022
Updated results from ongoing study on the effect of a BNT162b2 booster dose on anti-SARS-CoV-2 antibodies

Updated results from ongoing study on the effect of a BNT162b2 booster dose on anti-SARS-CoV-2 antibodies

11 Mar 2022

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback